The role of anti-Mullerian hormone and other correlates in patients with polycystic ovary syndrome

References

• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):1–7. doi:10.1016/j.fertnstert.2003.10.004.
   Web of Science ®Google Scholar
• Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10(8):2107–2111. doi:10.1093/oxfordjournals.humrep.a136243.
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Mateen S, Ahmad R, et al. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). J Assist Reprod Genet. 2022;39(11):2439–2473. doi:10.1007/s10815-022-02625-7.
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism. 2018;86:33–43. doi:10.1016/j.metabol.2017.09.016.
   PubMed Web of Science ®Google Scholar
• Ibáñez L, Oberfield SE, Witchel S, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr. 2017;88(6):371–395. doi:10.1159/000479371.
   PubMed Web of Science ®Google Scholar
• Harrison TNH, Chang RJ. Ovarian response to follicle-stimulating hormone in women with polycystic ovary syndrome is diminished compared to ovulatory controls. Clin Endocrinol (Oxf). 2022;97(3):310–318. doi:10.1111/cen.14708.
   PubMed Web of Science ®Google Scholar
• Vigier B, Picard JY, Tran D, et al. Production of anti-Müllerian hormone: another homology between sertoli and granulosa cells. Endocrinology. 1984;114(4):1315–1320. doi:10.1210/endo-114-4-1315.
   PubMed Web of Science ®Google Scholar
• Visser JA, de Jong FH, Laven JS, et al. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction. 2006;131(1):1–9. doi:10.1530/rep.1.00529.
   PubMed Web of Science ®Google Scholar
• di Clemente N, Josso N, Gouédard L, et al. Components of the anti-Müllerian hormone signaling pathway in gonads. Mol Cell Endocrinol. 2003;211(1–2):9–14. doi:10.1016/j.mce.2003.09.005.
   PubMed Web of Science ®Google Scholar
• Carlsson IB, Scott JE, Visser JA, et al. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod. 2006;21(9):2223–2227. doi:10.1093/humrep/del165.
   PubMed Web of Science ®Google Scholar
• McGee EA, Smith R, Spears N, et al. Müllerian inhibitory substance induces growth of rat preantral ovarian follicles. Biol Reprod. 2001;64(1):293–298. doi:10.1095/biolreprod64.1.293.
   PubMed Web of Science ®Google Scholar
• Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142(11):4891–4899. doi:10.1210/endo.142.11.8486.
   PubMed Web of Science ®Google Scholar
• Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88(12):5957–5962. doi:10.1210/jc.2003-030727.
   PubMed Web of Science ®Google Scholar
• Rudnicka E, Kunicki M, Calik-Ksepka A, et al. Anti-müllerian hormone in pathogenesis, diagnostic and treatment of PCOS. Int J Mol Sci. 2021;22(22):12507. doi:10.3390/ijms222212507.
   PubMed Web of Science ®Google Scholar
• Malhotra N, Mahey R, Cheluvaraju R, et al. Serum anti-mullerian hormone (AMH) levels among different PCOS phenotypes and its correlation with clinical, endocrine, and metabolic markers of PCOS. Reprod Sci. 2023;30(8):2554–2562. doi:10.1007/s43032-023-01195-y.
   PubMed Web of Science ®Google Scholar
• Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15(4):477–488. doi:10.1093/humupd/dmp008.
   PubMed Web of Science ®Google Scholar
• Saxena U, Ramani M, Singh P. Role of AMH as diagnostic tool for polycystic ovarian syndrome. J Obstet Gynaecol India. 2018;68(2):117–122. doi:10.1007/s13224-017-1066-4.
   PubMed Web of Science ®Google Scholar
• Piltonen TT, Komsi E, Morin-Papunen LC, et al. AMH as part of the diagnostic PCOS workup in large epidemiological studies. Eur J Endocrinol. 2023;188(6):547–554. doi:10.1093/ejendo/lvad065.
   PubMed Web of Science ®Google Scholar
• Sinha S, Sharan A, Sinha S. Anti-Mullerian hormone as a marker of ovarian reserve and function. Cureus. 2022;14(9):e29214. doi:10.7759/cureus.29214.
   PubMed Web of Science ®Google Scholar
• Ding T, Hardiman PJ, Petersen I, et al. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017;8(56):96351–96358. doi:10.18632/oncotarget.19180.
   PubMedGoogle Scholar
• Dargham SR, Ahmed L, Kilpatrick ES, et al. The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population. PLoS One. 2017;12(7):e0181467. doi:10.1371/journal.pone.0181467.
   PubMed Web of Science ®Google Scholar
• Sahmay S, Atakul N, Aydogan B, et al. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2013;92(12):1369–1374. doi:10.1111/aogs.12247.
   PubMed Web of Science ®Google Scholar
• Wiweko B, Maidarti M, Priangga MD, et al. Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. J Assist Reprod Genet. 2014;31(10):1311–1316. doi:10.1007/s10815-014-0300-6.
   PubMed Web of Science ®Google Scholar
• Rich-Edwards JW, Spiegelman D, Garland M, et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology. 2002;13(2):184–190. doi:10.1097/00001648-200203000-00013.
   PubMed Web of Science ®Google Scholar
• Sam S. Obesity and polycystic ovary syndrome. Obes Manag. 2007;3(2):69–73. doi:10.1089/obe.2007.0019.
   PubMedGoogle Scholar
• Dokuzeylül Güngör N, Güngör K, Celik N, et al. Impact of body mass index and vitamin D on serum AMH levels and antral follicle count in PCOS. Eur Rev Med Pharmacol Sci. 2023;27(1):179–187. doi:10.26355/eurrev_202301_30870.
   PubMed Web of Science ®Google Scholar
• Sharif E, Rahman S, Zia Y, et al. The frequency of polycystic ovary syndrome in young reproductive females in Qatar. Int J Womens Health. 2017;9:1–10. doi:10.2147/ijwh.S120027.
   PubMed Web of Science ®Google Scholar
• Dietz de Loos ALP, Jiskoot G, Timman R, et al. Improvements in PCOS characteristics and phenotype severity during a randomized controlled lifestyle intervention. Reprod Biomed Online. 2021;43(2):298–309. doi:10.1016/j.rbmo.2021.05.008.
   PubMed Web of Science ®Google Scholar
• Lobo RA. Hirsutism in polycystic ovary syndrome: current concepts. Clin Obstet Gynecol. 1991;34(4):817–826. doi:10.1097/00003081-199112000-00019.
   PubMed Web of Science ®Google Scholar
• McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic ovary syndrome. N Engl J Med. 2016;375(1):54–64. doi:10.1056/NEJMcp1514916.
   PubMed Web of Science ®Google Scholar
• Randall VA, Thornton MJ, Hamada K, et al. Mechanism of androgen action in cultured dermal papilla cells derived from human hair follicles with varying responses to androgens in vivo. J Invest Dermatol. 1992;98(6 Suppl):86s–91s. doi:10.1111/1523-1747.ep12462307.
   PubMed Web of Science ®Google Scholar
• Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019;3(8):1545–1573. doi:10.1210/js.2019-00078.
   PubMed Web of Science ®Google Scholar
• Wang HS, Chard T. IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. J Endocrinol. 1999;161(1):1–13. doi:10.1677/joe.0.1610001.
   PubMed Web of Science ®Google Scholar
• Mantzou D, Stamou MI, Armeni AK, et al. Impaired sexual function in young women with PCOS: the detrimental effect of anovulation. J Sex Med. 2021;18(11):1872–1879. doi:10.1016/j.jsxm.2021.09.004.
   PubMed Web of Science ®Google Scholar
• Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstetr Gynecol. 1935;29(2):181–191. doi:10.1016/S0002-9378(15)30642-6.
   Google Scholar
• Palomaki GE, Kalra B, Kumar T, et al. Adjusting antimüllerian hormone levels for age and body mass index improves detection of polycystic ovary syndrome. Fertil Steril. 2020;113(4):876–884.e2. doi:10.1016/j.fertnstert.2019.12.012.
   PubMed Web of Science ®Google Scholar
• Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–379. doi:10.1016/j.fertnstert.2018.05.004.
   PubMed Web of Science ®Google Scholar
• Pigny P, Jonard S, Robert Y, et al. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(3):941–945. doi:10.1210/jc.2005-2076.
   PubMed Web of Science ®Google Scholar
• Dewailly D, Pigny P, Soudan B, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab. 2010;95(9):4399–4405. doi:10.1210/jc.2010-0334.
   PubMed Web of Science ®Google Scholar
• Woo HY, Kim KH, Rhee EJ, et al. Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J. 2012;59(9):781–790. doi:10.1507/endocrj.ej12-0055.
   PubMed Web of Science ®Google Scholar
• Saikumar P, Selvi VK, Prabhu K, et al. Anti mullerian hormone: a potential marker for recruited non growing follicle of ovarian pool in women with polycystic ovarian syndrome. J Clin Diagn Res. 2013;7(9):1866–1869. doi:10.7860/jcdr/2013/5530.3337.
   PubMedGoogle Scholar
• Chao KC, Ho CH, Shyong WY, et al. Anti-mullerian hormone serum level as a predictive marker of ovarian function in taiwanese women. J Chin Med Assoc. 2012;75(2):70–74. doi:10.1016/j.jcma.2011.12.007.
   PubMed Web of Science ®Google Scholar
• Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123–3129. Nov doi:10.1093/humrep/der297.
   PubMed Web of Science ®Google Scholar
• Al-Hashimy D, Al-Rikaby H, Al-Khayaat E. Study of some hormonal disorders associated with polycystic ovarian syndrome in women in Thi Qar governorate. J Coll Educ Pure Sci. 2019;9(2):25–31. doi:10.32792/utq.jceps.09.02.03.
   Google Scholar
• Malini NA, Roy George K. Evaluation of different ranges of LH: FSH ratios in polycystic ovarian syndrome (PCOS) - clinical based case control study. Gen Comp Endocrinol. 2018;260:51–57. doi:10.1016/j.ygcen.2017.12.007.
   PubMed Web of Science ®Google Scholar
• Berger MJ, Taymor ML, Patton WC. Gonadotropin levels and secretory patterns in patients with typical and atypical polycystic ovarian disease. Fertil Steril. 1975;26(7):619–626. doi:10.1016/S0015-0282(16)41228-8.
   PubMed Web of Science ®Google Scholar
• Hernández-Jiménez JL, Barrera D, Espinoza-Simón E, et al. Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance. Gynecol Endocrinol. 2022;38(1):2–9. doi:10.1080/09513590.2021.2003326.
   PubMed Web of Science ®Google Scholar
• Ezeh U, Pisarska MD, Azziz R. Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome. Hum Reprod. 2022;37(3):553–564. doi:10.1093/humrep/deac001.
   PubMed Web of Science ®Google Scholar
• Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82(7):2248–2256. doi:10.1210/jcem.82.7.4105.
   PubMed Web of Science ®Google Scholar
• Hayashida SA, Marcondes JA, Soares JMJr, et al. Evaluation of macroprolactinemia in 259 women under investigation for polycystic ovary syndrome. Clin Endocrinol (Oxf). 2014;80(4):616–618. doi:10.1111/cen.12266.
   PubMedGoogle Scholar
• Parsanezhad ME, Alborzi S, Jahromi BN. A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level. Int J Fertil Womens Med. 2002;47(6):272–277.
   PubMedGoogle Scholar
• Filho RB, Domingues L, Naves L, et al. Polycystic ovary syndrome and hyperprolactinemia are distinct entities. Gynecol Endocrinol. 2007;23(5):267–272. doi:10.1080/09513590701297708.
   PubMed Web of Science ®Google Scholar
• Krul-Poel YH, Snackey C, Louwers Y, et al. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. Eur J Endocrinol. 2013;169(6):853–865. Dec doi:10.1530/eje-13-0617.
   PubMed Web of Science ®Google Scholar
• Davis EM, Peck JD, Hansen KR, et al. Associations between vitamin D levels and polycystic ovary syndrome phenotypes. Minerva Endocrinol. 2019;44(2):176–184. doi:10.23736/s0391-1977.18.02824-9.
   PubMed Web of Science ®Google Scholar
• Hahn S, Haselhorst U, Tan S, et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2006;114(10):577–583. doi:10.1055/s-2006-948308.
   PubMed Web of Science ®Google Scholar
• Contreras-Bolívar V, García-Fontana B, García-Fontana C, et al. Mechanisms involved in the relationship between vitamin D and insulin resistance: impact on clinical practice. Nutrients. 2021;13(10):3491. doi:10.3390/nu13103491.
   PubMed Web of Science ®Google Scholar
• Wehr E, Trummer O, Giuliani A, et al. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol. 2011;164(5):741–749. doi:10.1530/eje-11-0134.
   PubMed Web of Science ®Google Scholar
• Kotsa K, Yavropoulou MP, Anastasiou O, et al. Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril. 2009;92(3):1053–1058. doi:10.1016/j.fertnstert.2008.07.1757.
   PubMed Web of Science ®Google Scholar
• Pal L, Berry A, Coraluzzi L, et al. Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. Gynecol Endocrinol. 2012;28(12):965–968. doi:10.3109/09513590.2012.696753.
   PubMed Web of Science ®Google Scholar
• Ardabili HR, Gargari BP, Farzadi L. Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr Res. 2012;32(3):195–201. doi:10.1016/j.nutres.2012.02.001.
   PubMed Web of Science ®Google Scholar